Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

NCT05822609 · Recruiting

Last updated 2026-07-28

This clinical trial is testing whether the medication semaglutide can help people with type 1 diabetes and diabetic kidney disease.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 60 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2024-04 · est. completion 2027-12

Where 4 sites · Canada, United States

What this study is testing ClinicalTrials.gov NCT05822609 ↗

Description as written by the study sponsor.

The primary objective of this study is to determine the effects of semaglutide on change in albuminuria from baseline to 26 weeks in type 1 diabetes. The secondary objective is to determine the effects of semaglutide on change in kidney parameters (including kidney oxygenation and function) measured by MRI from baseline to 26 weeks in type 1 diabetes. Other objectives are to determine the glycemic effects and safety of semaglutide in type 1 diabetes.

Treatments tested

Semaglutide Drug

1.0 mg
Placebo Other

Placebo

Main thing measured	Change in urine albumin excretion
Sponsor	University of Washington
Conditions studied	Diabetic Kidney Disease, Type 1 Diabetes
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05822609 ↗